On July 29th, 2026, the FDA will convene an Advisory Committee meeting to evaluate Deramiocel, Capricor Therapeutics’ investigational therapy for Duchenne muscular dystrophy. These meetings are an important step in the regulatory process, bringing together independent experts, community voices, and scientific data to inform FDA’s review. For our community, this moment represents more than a discussion of data; it is about progress, urgency, and the realities of living with Duchenne.
At PPMD, our role is to ensure that the lived experiences of individuals and families are reflected alongside the clinical evidence. As we look ahead to this meeting, we urge the FDA to consider several critical factors.
Conduct a Comprehensive Review of the Totality of Evidence
PPMD encourages FDA to conduct a comprehensive review of the totality of evidence that reflects the central tenet of their benefit-risk assessment framework: evaluate the potential benefits and risks of Deramiocel, while actively incorporating the patient and caregiver perspective.
Recognize the Urgency of Duchenne Cardiomyopathy
For individuals living with Duchenne, cardiomyopathy remains one of the most serious and life-threatening complications. It is a constant and growing concern for patients and families alike. Congress has directed the FDA to exercise regulatory adaptability when evaluating therapies for serious and life-threatening rare diseases. Therapies that may alter the trajectory of heart disease, even incrementally, deserve thoughtful consideration.
Understand the Importance of Upper Limb Function
While cardiac outcomes are critical, maintaining upper limb function is also deeply important to individuals living with Duchenne. The ability to feed oneself, operate a wheelchair, use technology, or maintain independence in daily activities has profound implications for quality of life. These outcomes should be given appropriate weight when assessing a therapy’s overall benefit.
Weigh Risk and Benefit in the Context of a Progressive Disease
In Duchenne, time matters. Disease progression does not pause, and the window for intervention is limited. PPMD urges FDA to weigh the seriousness of Duchenne against the potential benefits of therapies that may offer incremental progress. Even modest advances can be meaningful in a disease where preserving function and slowing decline can change the course of daily life.
As FDA evaluates the benefit-risk profile of this therapy, we encourage a focus on meaningful advances and tangible impact for individuals and families navigating Duchenne every day. Progress in rare diseases is often incremental, but each step forward matters.
The Role of FDA in Final Decision-Making
Advisory Committee meetings are just one part of the regulatory process. Ultimately, FDA reviewers are responsible for making an independent determination about the approval of a potential therapy. PPMD respects FDA’s responsibility to independently evaluate all available evidence, consider the recommendations of the Advisory Committee, and reach a decision grounded in both scientific rigor and the realities of living with Duchenne
Looking Ahead
The July 29th Advisory Committee meeting is an important milestone for the Duchenne community. We are grateful to the individuals and families who will share their experiences, and to the experts who will thoughtfully evaluate the data.
PPMD remains committed to ensuring that the voices of our community are heard, and that urgency, lived experience, and the need for continued progress remain at the forefront of every decision.
The post Ahead of the July 29 Advisory Committee: We Urge the FDA to Consider the Totality of Evidence appeared first on Parent Project Muscular Dystrophy.